Neuanfang nach R/S (2010)

Seite 1 von 1
neuester Beitrag:  06.08.10 20:25
eröffnet am: 20.07.10 14:03 von: Hunter20nov Anzahl Beiträge: 5
neuester Beitrag: 06.08.10 20:25 von: Chalifmann3 Leser gesamt: 2703
davon Heute: 2
bewertet mit 1 Stern

20.07.10 14:03 #1 Neuanfang nach R/S (2010)

So der R/S sollte nun ja überwunden sein und es wurde auch ein Boden gefunden. Es sind gut gerundet 7,4 Mio Aktien nach dem Splitt übrig geblieben. ( Aktienanzahl )

Ich denke über kurz oder lang nach guten News die ich anfang/mitte Oktober erwarte wenn nicht früher wird die Aktie sich bei gut 5 $ einpendeln und von da aus eine kleine langsame Rally (über 6 Monate) nach oben machen und kann dann endlich von Zockeraktie zu seriöser Aktie wechseln. Aber gut das ist nur meine Meinung.  Aber Potenzial hat die Firma.  

 

Grüße

 

 

 
27.07.10 15:57 #2 new 26.07.2010
26.07.2010 18:36
Mohamed Hachicha, Ph.D. Joins NexMed, Inc. as Vice President-Research and Development for NexMed, USA

NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, announced today that Mohamed Hachicha, Ph.D., has been appointed to the position of Vice President, Research and Development for NexMed USA, effective immediately.

Dr. Hachicha brings to NexMed 15 years of experience in the pharmaceutical and biotechnology industries. Prior to joining NexMed, from 2005 to 2010, Dr. Hachicha served as Senior Principal Scientist in the Pharmacology and Drug Discovery Department at Forest Laboratories, where, among other things, he was responsible for managing and coordinating two of the company's discovery research programs. From 1999 to 2005, he was Principal Investigator in the Molecular Pharmacology Department at Purdue Pharma, L.P., where he managed and coordinated the company's multi-disciplinary discovery research program. Dr. Hachicha began his career as a Research Scientist in the Discovery Department at Pharmacopeia, Inc., and prior, conducted post doctorate research focused on inflammatory diseases at Harvard Medical School, where he authored key publications in the field of lipoxins.

Dr. Hachicha received his B.S. degree in Biochemistry from the University of Algiers, Algeria, and both his M.Sc. and Ph.D. in Immunology from Laval University, Canada. His technical expertise is in both in-vitro and in-vivo pharmacology. He is the recipient of many industry awards and has authored or co-authored a number of articles in peer-reviewed journals.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, noted, "Dr. Hachicha's extensive experience and proven success in the field of drug development, from target identification and validation to the selection of clinical development targets, made him the best candidate for the key role of Vice President, Research and Development for NexMed USA and we are delighted to welcome him to the Company. Dr. Hachicha's expertise will be instrumental as we move ahead with our strategy to maximize the possibilities for the NexACT technology."

About NexMed

Backed by a solid, revenue generating CRO business, including a stable of over 300 clients and extensive research and development capabilities, NexMed has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth will be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that the Company will be able to successfully license its NexACT technology or proprietary products under development.

Contacts:

NexMed, Inc.
Edward Cox, 858-926-5811
V.P. Investor Relations
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com



© 2010 Business Wire

http://www.finanznachrichten.de/...development-for-nexmed-usa-004.htm  
04.08.10 12:35 #3 2,31 € noch zu teuer für einstieg
ich warte noch bis 1,60€  
06.08.10 19:48 #4 Richtig, hier ist abwarten angesagt
Nach dem Split wird es immer Leute geben die verrückt sind und verkaufen...
weil sie denken der Kurs sei gestiegen.

2.00 $ können schnell erreicht werden.
-----------
Emotionen und Psychologie leiten die Börse...

Y M
06.08.10 20:25 #5 Dieses teil
ist wohl so ziemlich das allerletzte,was sich im biotechsegment "etabliert" hat.Ich erinnere mich sofort an Macrochem,die es damals ebenfalls mit Topical creame erectyle dysfunktion versucht haben,das Papier ist mittlerweile von 10$ auf 0,0001$ gefallen und delistet,dito !

MFG
Chali  
Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen:    


Bitte warten...